Global tuberculosis incidence has declined marginally over the past decade, and
tuberculosis remains out of control in several parts of the world including Africa and Asia …

The continuing spread of drug-resistant tuberculosis (TB) is one of the most urgent and
difficult challenges facing global TB control. Patients who are infected with strains resistant …

Background Tuberculous meningitis is often lethal. Early antituberculosis treatment and
adjunctive treatment with glucocorticoids improve survival, but nearly one third of patients …

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are generally
thought to have high mortality rates. However, many cases can be treated with the right …

Background New drugs, but also shorter, better-tolerated regimens are needed to tackle the
high global burden of tuberculosis complicated by drug resistance and retroviral disease …

The cornerstone of tuberculosis management is a 6‐month course of isoniazid, rifampicin,
pyrazinamide and ethambutol. Compliance is crucial for curing tuberculosis. Adverse effects …

SETTING: Niger National Tuberculosis Programme. Regions supported by the Damien
Foundation. OBJECTIVE: To evaluate the effectiveness of a short-course standardised …

Drug-resistant tuberculosis (DR-TB) remains a global crisis due to the increasing incidence
of drug-resistant forms of the disease, gaps in detection and prevention, models of care, and …

SETTING: Nine countries in West and Central Africa. OBJECTIVE: To assess outcomes and
adverse drug events of a standardised 9-month treatment regimen for multidrug-resistant …

Background New treatments are needed to shorten the time required to cure tuberculosis
and to treat drug-resistant strains. The fluoroquinolone moxifloxacin is a promising new …